Administrative information
Title {1} | Effects of a peripherally acting µ-opioid receptor antagonist for the prevention of recurrent acute pancreatitis: study protocol for an investigator-initiated, randomized, placebo-controlled, double-blind clinical trial. (PAMORA-RAP trial). |
Trial registration {2a and 2b}. | EudraCT no. 2021–000069-34 Clinicaltrials.gov NCT04966559 registered July 8, 2021, https://clinicaltrials.gov/ct2/show/NCT04966559 |
Protocol version {3} | 22.11.2021 Version 1.22 |
Funding {4} | The study is funded as part of an unrestricted grant by the Novo Nordisk Foundation. Shionogi BV also supports the study through a supply of study drugs. |
Author details {5a} |
1 Centre for Pancreatic Diseases and Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark
2 Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
3 Department of Radiology, Aalborg University Hospital, Aalborg, Denmark
4 Department of Mathematical Sciences, Aalborg University, Aalborg, Denmark
5 Gastrounit, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark
6 Odense Pancreas Centre (OPAC), HPB Section, Department of Surgery, Odense University Hospital, Odense, Denmark
7 Digestive Disease Centre K, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
8 Department for Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden |
Name and contact information for the trial sponsor {5b} | Asbjørn Mohr Drewes, Professor, MD, PhD, DMSc Centre for Pancreatic Diseases and Mech-Sense Department of Gastroenterology & Hepatology Aalborg University Hospital 9000 Aalborg, Denmark Telephone: + 45 97 66 35 62 E-mail: amd@rn.dk |
Role of sponsor {5c} | The PAMORA-RAP study is an investigator-initiated trial. The financial supporters have no influence on study design, data collection, or publication. |
Introduction
Background and rationale {6a}
Objectives {7}
-
Frequency and severity of pain attacks
-
Patient-reported treatment efficacy
-
Quality of life
-
Gastrointestinal symptoms and bowel function
-
The proportion of patients with new-onset diabetes and new-onset exocrine pancreatic insufficiency along with the progression of known pancreatic insufficiency measured as changes in the use of relevant medication
-
Health care resource utilization
-
Adherence to treatment and frequency of adverse events
-
Ductal and parenchymal pancreatic morphology evaluated by MRI
-
Circulating blood markers of fibrosis and inflammation
Trial design {8}
Methods: participants, interventions, and outcomes
Study setting {9}
Eligibility criteria {10}
Inclusion criteria
-
Signed informed consent before any study-specific procedures
-
Able to read and understand Danish or Swedish (depending on the study site)
-
Adults aged 18 to 74 years (both inclusive)
-
A diagnosis of recurrent acute pancreatitis with at least one attack of acute pancreatitis within the last 12 months and at least two attacks within 5 years (confirmed as defined by the revised Atlanta Criteria [17])
-
Clinically stable at the time of inclusion defined by no objective, radiological or biochemical signs of acute pancreatitis or other diseases that require hospitalization
-
The researcher finds that the participant understands what the study entails, is capable of following instructions, can attend when needed, and is expected to complete the study
-
The investigator will ensure that fertile female participants have a negative pregnancy test before treatment initiation and use contraception during the study period. The following methods of contraception, if properly used, are generally considered reliable: oral contraceptives, patch contraceptives, injection contraceptives, vaginal contraceptive ring, intrauterine device, surgical sterilization (bilateral tubal ligation), vasectomized partner, double barrier (condom and pessary), or sexual abstinence. Methods of contraception will be documented in the source documents
Exclusion criteria
-
Known hypersensitivity towards study medication
-
Patients with known or suspected gastrointestinal obstruction or perforation or patients at increased risk of recurrent obstruction due to the potential for gastrointestinal perforation (e.g. peptic ulcer disease, acute colonic pseudo-obstruction, malignancy of the GI tract, Crohn’s disease)
-
Previous pancreatic surgery including pancreaticoduodenectomy or other procedures involving the pancreatic head and sphincter of Oddi
-
Known severe renal insufficiency (defined as estimated glomerular filtration rate < 30 ml/min)
-
Female participants that are lactating
-
Pre-existing severe comorbidities (evaluated by the investigator prior to inclusion)
-
Attack of acute pancreatitis requiring admission within 4 weeks prior to inclusion
-
Gallstone aetiology of recurrent acute pancreatitis (magnetic resonance cholangiopancreatography or endoscopic ultrasound excluding biliary stones must be available prior to enrolment)
-
Treatment with strong CYP3A4-inhibitors (itraconazole, ketoconazole, ritonavir, indinavir, saquinavir, telithromycin, grapefruit juice and clarithromycin), strong CYP3A inducers (e.g. St. John’s wort (Hypericum perforatum), rifampicin, carbamazepine, phenobarbital and phenytoin) or P-glycoprotein inhibitors (e.g. cyclosporine).
Who will take informed consent? {26a}
Additional consent provisions for collection and use of participant data and biological specimens {26b}
Interventions
Explanation for the choice of comparators {6b}
Intervention description {11a}
Criteria for discontinuing or modifying allocated interventions {11b}
-
It is the wish of the participant for any reason
-
The investigator judges it necessary due to medical reasons
-
The investigator judges severe non-compliance to protocol
-
They experience intolerable side effects despite tapering the dose of naldemedine to 0.2 mg (or matching placebo) every other day
Strategies to improve adherence to interventions {11c}
Relevant concomitant care permitted or prohibited during the trial {11d}
Provisions for post-trial care {30}
Outcomes {12}
Primary outcome
Secondary outcomes
-
Difference between treatment groups in disease severity assessed by the Atlanta Criteria
-
The difference between treatment groups in frequency and severity of pain attacks (without fulfilling acute pancreatitis criteria), assessed by questionnaires and monthly interviews after the 12-month period
-
Difference in patient’s global impression of change between treatment groups assessed by a questionnaire at 12 months follow-up
-
Changes in quality of life between treatment groups from baseline to 12 months follow-up assessed by a questionnaire
-
Changes in gastrointestinal symptoms and bowel function between treatment groups from baseline to 12 months follow-up assessed by questionnaires
-
Proportion of patients with new-onset diabetes according to the WHO criteria [18] and changes in endocrine pancreas function between treatment groups from baseline to 12 months follow-up assessed by haemoglobin A1c (HbA1c)
-
Proportion of newly diagnosed exocrine pancreatic insufficiency defined by the use of pancreatic enzyme replacement therapy or changes in exocrine pancreas function between treatment groups from baseline to 12 months follow-up assessed by a faecal-elastase test
-
Difference between treatment groups in health care resource utilization (measured in frequency and type of health services used, e.g. admission rate and duration) during the 12-months treatment period
-
Difference between treatment groups in adherence to treatment and frequency of adverse events during the 12-months treatment period assessed by study drug diary, return of unused medicine, and regular interviews
Explorative outcomes
-
Changes in pancreatic morphology (pancreas volume/size, fibrosis, fatty infiltration, and ductal pathology) between treatment groups from baseline to 12 months follow-up measured by MRI
-
Difference in circulating markers of fibrosis and inflammation from baseline to 12 months follow-up
Participant timeline {13}
Sample size {14}
-
Included recurrent acute pancreatitis patients will have one pancreatitis attack at least once pr. year
-
Naldemedine is expected to reduce the pancreatitis attack rate by 50%
-
Power is set to 90% at a 2-sided alpha level of 0.05